Monoclonal anti mouse jam c antibody clone h33

To test the effects of JAM-C blockade in vivo, a monoclonal anti-mouse JAM-C antibody (clone H33; Millipore, Billerica, MA, USA) or control immunoglobulin G (IgG) was administered i.p. at 1.5 mg/kg on days 1 and 2 following IRI induction.

Male C57BL/6 mice (7- to 8-week-old) were purchased from Orient (Charles River Korea, Seoul, Korea) and allowed unrestricted access to food and water before experimentation began. Animal care complied with the rules of the Animal Care Committee of Korea University for the use of laboratory animals in research. Cisplatin (Sigma-Aldrich, St. Louis, MO, USA) was diluted in normal saline to a final concentration of 2 mg/mL. Cisplatin- treated mice were given a single intraperitoneal injection of Cisplatin (18 mg/kg), while a control group received the same volume of normal saline. To test the effect of a JAM-C blocking antibody in the recovery phase of Cisplatin-induced AKI, either a monoclonal anti-mouse JAM-C antibody (clone H33, Millipore, Billerica, MA, USA) or a control immunoglobulin G (IgG) was administered via intraperitoneal injection at 1.5 mg/kg on day 4 and 5 following Cisplatin injection. Mice were sacrificed on days 4, 5, or 6 days after Cisplatin administration. Their blood was collected by intracardiac puncture, and both kidneys were processed for histological examination and RNA isolation.